Adaptive Biotechnologies Corporation
Revenue Breakdown
| Fiscal Year | MRD | Immune Medicine |
|---|---|---|
| FY2020 | $32.6M | $65.7M |
| FY2021 | $66.2M | $88.1M |
| FY2022 | $87.1M | $98.2M |
| FY2023 | $102.7M | $67.5M |
| FY2024 | $145.5M | $33.4M |
| FY2025 | $212.3M | $64.6M |
Revenue Breakdown
| Fiscal Year | MRD | Immune Medicine |
|---|---|---|
| FY2020 | $32.6M | $65.7M |
| FY2021 | $66.2M | $88.1M |
| FY2022 | $87.1M | $98.2M |
| FY2023 | $102.7M | $67.5M |
| FY2024 | $145.5M | $33.4M |
| FY2025 | $212.3M | $64.6M |